摘要
目的:探讨尿激酶联合冠心宁注射液治疗不稳定型心绞痛的临床疗效。方法:选取本院2012年1月-2013年6月收治的100例不稳定型心绞痛患者,按随机数字表法将其分为观察组和对照组各50例,对照组给予常规药物治疗如硝酸酯类、低分子肝素、肠溶阿司匹林、波立维(氯吡格雷)、血管紧张素转换酶抑制剂(ACEI)、β受体阻滞剂等;观察组在常规药物治疗的基础上给予尿激酶25万U联合冠心宁注射液20 mL,静脉点滴1次/d,连用2周。观察比较两组的临床疗效、不良事件发生情况和血液流变指标的变化。结果:观察组的治疗有效率94.0%,明显优于对照组的68.0%,比较差异有统计学意义(P<0.05);两组不良事件发生率比较差异无统计学意义(P>0.05)。治疗后,两组患者的全血黏度明显降低,且观察组改善情况明显优于对照组,比较差异有统计学意义(P<0.05)。结论:在常规药物的基础上使用尿激酶联合冠心宁注射液治疗不稳定型心绞痛临床疗效显著,且安全可靠,值得临床推广。
Objective:To explore the clinical effect of urokinase combined with Guanxinning Injection in the treatment of unstable angina pectoris.Method:100 patients with unstable angina pectoris in our hospital from January 2012 to June 2013 were selected,they were randomly divided into the observation group and the control group,50 cases in each group.The control group was given routine drug treatment such as nitrate,low molecular weight heparin,aspirin,clopidogrel (Plavix),angiotensin converting enzyme inhibitor(ACEI),βreceptor blockers;The observation group on the basis of the conventional therapy was treated with urokinase 250 000 U combined with Guanxinning Injection 20 mL,intravenous drip of 1 time/day,for two weeks.The clinical curative effects,occurrence of adverse events and the change of blood rheology indexes of the two groups were observed and compared.Result:The effective rate of the observation group was 94.0%,it was significantly better than the control group(68.0%),the difference was statistically significant(P〈0.05).The incidence of adverse events of the two group had no significant difference(P〉0.05).After treatment,blood viscosity of two groups of patients decreased significantly,and the observation group improved more significantly than the control group,the difference was statistically significant(P〈0.05).Conclusion:The clinical effect of urokinase combined with Guanxinning Injection therapy based on the routine drug in the treatment of unstable angina pectoris is significantly,safe and reliable,it is worthy of clinical application.
出处
《中国医学创新》
CAS
2014年第8期42-44,共3页
Medical Innovation of China